Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicita Andreotti

Showing results (171-180 of 236) with videos related to

Pageof 24
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|September 25, 2018
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a reviewEliano P Navarese, Felicita Andreotti, Paolo Raggi, et al.
Platelets|June 2, 2011
Diurnal variation in platelet inhibition by clopidogrelMarek Kozinski, Liliana Bielis, Joanna Wisniewska-Szmyt, et al.
The American Journal of Cardiology|January 29, 2013
Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitusEliano Pio Navarese, Antonino Buffon, Felicita Andreotti, et al.
JACC. Cardiovascular Imaging|August 4, 2025
Advanced Analyses of Coronary Computed Tomography Angiography to Predict Future Cardiac Events: A Meta-AnalysisEmiliano Bianchini, Foziyah Alqahtani, Sara Alsubai, et al.
JACC. Cardiovascular Interventions|January 25, 2015
Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromeEliano Pio Navarese, Volker Schulze, Felicita Andreotti, et al.
Annals of Internal Medicine|February 20, 2013
Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysisEliano P Navarese, Paul A Gurbel, Felicita Andreotti, et al.
European Heart Journal|March 1, 2005
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular functionAntonio Maria Leone, Sergio Rutella, Giuseppina Bonanno, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|March 6, 2009
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized studyGiovanni Paolo Talarico, Marta Brancati, Francesco Burzotta, et al.
European Heart Journal|July 11, 2025
Sex differences in dual antiplatelet therapy de-escalation strategies after percutaneous coronary intervention: a network meta-analysisGiovanni Occhipinti, Claudio Laudani, Mattia Galli, et al.
European Heart Journal|March 8, 2025
Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 monthsRobert A Byrne, Marco Valgimigli, Deepak L Bhatt, et al.
Pageof 24

Showing results (171-180 of 236) with videos related to

Sort By:
Pageof 24
European Heart Journal. Cardiovascular Pharmacotherapy|September 25, 2018
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a reviewEliano P Navarese, Felicita Andreotti, Paolo Raggi, et al.
Platelets|June 2, 2011
Diurnal variation in platelet inhibition by clopidogrelMarek Kozinski, Liliana Bielis, Joanna Wisniewska-Szmyt, et al.
The American Journal of Cardiology|January 29, 2013
Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitusEliano Pio Navarese, Antonino Buffon, Felicita Andreotti, et al.
JACC. Cardiovascular Imaging|August 4, 2025
Advanced Analyses of Coronary Computed Tomography Angiography to Predict Future Cardiac Events: A Meta-AnalysisEmiliano Bianchini, Foziyah Alqahtani, Sara Alsubai, et al.
JACC. Cardiovascular Interventions|January 25, 2015
Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromeEliano Pio Navarese, Volker Schulze, Felicita Andreotti, et al.
Annals of Internal Medicine|February 20, 2013
Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysisEliano P Navarese, Paul A Gurbel, Felicita Andreotti, et al.
European Heart Journal|March 1, 2005
Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular functionAntonio Maria Leone, Sergio Rutella, Giuseppina Bonanno, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|March 6, 2009
Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized studyGiovanni Paolo Talarico, Marta Brancati, Francesco Burzotta, et al.
European Heart Journal|July 11, 2025
Sex differences in dual antiplatelet therapy de-escalation strategies after percutaneous coronary intervention: a network meta-analysisGiovanni Occhipinti, Claudio Laudani, Mattia Galli, et al.
European Heart Journal|March 8, 2025
Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 monthsRobert A Byrne, Marco Valgimigli, Deepak L Bhatt, et al.
Pageof 24